Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 29, 2010

GSK and EyeGate to Evaluate Iontophoresis System for Drug Delivery to Eye Tissues

GSK and EyeGate are teaming up on drug delivery to eye tissues using the latter’s EyeGate II system. (© nyul - Fotolia.com)

  • EyeGate Pharma and GlaxoSmithKline (GSK) will collaborate on evaluating the delivery of a number of the latter’s therapies to posterior and anterior eye tissues using the EyeGate® II delivery system.

    EyeGate II is a noninvasive transcleral iontophoresis delivery platform. The approach uses an electrical field created by a low-level electrical current to ionize a drug and modify the permeability of the cells, which allows delivery of the drug through different tissues to targeted areas.

    The deal with GSK comes a month or so after EyeGate reported positive results from a Phase II trial evaluating its own lead product, EGP-437, in the treatment of anterior uveitis. A Phase II trial in dry-eye patients was successfully completed in 2009.

    EGP-437 is a dexamethasone-derived corticosteroid solution delivered using the EyeGate II technology. Data from the recently reported anterior uveitis study showed that a single treatment with EGP-437 led to half the subjects achieving an anterior cell score of zero within two weeks. By 28 days post-treatment the majority of patients had achieved cell scores of zero and required no further treatment, the firm claims.

    EyeGate says it expects to start a Phase III trial with EGP-437 in dry-eye patients during the first half of 2010. EGP-437 is also in Phase II development as a treatment for corneal-graft rejection (CGR) and has been granted orphan drug designation in the U.S. for the CGR indication. In January the firm raised $22.6 million in Series D venture financing to progress its clinical program.

Related content